Yüksel Ürün: Adjuvant nivolumab vs placebo in localized RCC patients at high recurrence risk post-nephrectomy by Robert J. Motzer

Yüksel Ürün shared a post on X:

“CheckMate 914 (Part B) failed to show DFS improvement with adjuvant nivolumab vs placebo in localized RCC patients at high recurrence risk post-nephrectomy.”

Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial

Authors:  Robert J. Motzer, Axel Bex, Paul Russo, Yoshihiko Tomita, Hernan Javier Cutuli, Carlos Rojas, Marine Gross-Goupil, Giovanni Schinzari, Bohuslav Melichar, Philippe Barthélémy, Abraham Ruiz Garcia, Jeffrey Sosman, Marc-Oliver Grimm, Jeffrey C. Goh, Cristina Suarez, Christian K. Kollmannsberger, Suresh G. Nair, Brian M. Shuch, Jian Huang, Burcin Simsek, Julia Spiridigliozzi, Chung-Wei Lee, Maximiliano van Kooten Losio, and Viktor Grünwald.

Source: Yüksel Ürün/X

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.